title: Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors.
abstract: Zolpidem and alpidem, two imidazopyridines with high affinity for the type I benzodiazepine recognition site, have recently been proposed as preferential hypnotic (zolpidem) and anxiolytic (alpidem) drugs notable for the minor incidence of side-effects. To further characterize the molecular mechanism involved in the action of these drugs, we studied their effects in comparison with those of diazepam on the spontaneous electrical activity of substantia nigra pars reticulata (SNR) neurons. These cells have been shown to be extremely sensitive to various positive and negative modulators of GABAergic transmission. All three drugs consistently produced a dose-dependent (0.03-8.0 mg/kg i.v.) inhibition of the firing of SNR cells when administered as a single bolus. However, zolpidem was more potent and efficacious than diazepam or alpidem. The ID50s were 0.076, 0.492 and 0.821 mg/kg, respectively. When the drugs were injected in exponentially (ratio 2) increasing doses up to 8.0 mg/kg, the rank order for tachyphylaxis was zolpidem much greater than diazepam greater than alpidem. Since the effects of the drugs were abolished and prevented by a small dose (0.5 mg/kg i.v.) of flumazenil (Ro 15-1788), it is likely that the effects were mediated through activation of benzodiazepine receptors. The results indicate that the hypnotic, zolpidem, has a more potent inhibitory action on SNR cell activity than the anxiolytics, alpidem and diazepam.
authors.affiliation: Department of Experimental Biology, University of Cagliari, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Mereu
authors.forename: G
authors.initials: G
authors.lastname: Carcangiu
authors.forename: A
authors.initials: A
authors.lastname: Concas
authors.forename: N
authors.initials: N
authors.lastname: Passino
authors.forename: G
authors.initials: G
authors.lastname: Biggio
mesh_terms: D000200:Action Potentials; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D003975:Diazepam / Q000494:pharmacology; D005442:Flumazenil / Q000494:pharmacology; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects*; D012154:Reticular Formation / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D000077334:Zolpidem
chemical_list: D014151:Anti-Anxiety Agents; D006993:Hypnotics and Sedatives; D007093:Imidazoles; D011725:Pyridines; D011963:Receptors, GABA-A; D005442:Flumazenil; D000077334:Zolpidem; C052036:alpidem; D003975:Diazepam